* Enveric Biosciences Inc reported a quarterly adjusted loss of $1.47 per share for the quarter ended in December. The mean expectation of three analysts for the quarter was for a loss of $1.54 per share. Wall Street expected results to range from $-1.59 to $-1.50 per share.
* Reported revenue was zero; analysts expected zero.
* Enveric Biosciences Inc's reported EPS for the quarter was a loss of $1.47.
* The company reported a quarterly loss of $3.44 million.
* Enveric Biosciences Inc shares had fallen by 21.5% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 2.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Enveric Biosciences Inc is $10.00 This summary was machine generated from LSEG data March 29 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -1.54 -1.47 Beat
Sep. 30 2023 -2.09 -1.30 Beat
Jun. 30 2023 -0.65 -3.04 Missed
Comments